List of Excipients in Branded Drug EVOTAZ

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ER Squibb & Sons LLC	EVOTAZ	atazanavir and cobicistat	0003-3641	CELLULOSE, MICROCRYSTALLINE	2029-09-03
ER Squibb & Sons LLC	EVOTAZ	atazanavir and cobicistat	0003-3641	CROSCARMELLOSE SODIUM	2029-09-03
ER Squibb & Sons LLC	EVOTAZ	atazanavir and cobicistat	0003-3641	CROSPOVIDONE	2029-09-03

EVOTAZ Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

EVOTAZ is a once-daily fixed-dose tablet containing atazanavir sulfate equivalent to 300 mg of atazanavir and cobicistat 150 mg. Its commercial opportunity is concentrated in generic or alternative fixed-dose development, excipient substitution, supply-chain resilience, and differentiated formulations rather than in new chemical-entity protection. The primary technical challenge is achieving bioequivalence for two poorly soluble, pharmacokinetically sensitive compounds while preserving food-dependent absorption and tablet stability.

What is EVOTAZ and how is it used?

EVOTAZ combines a protease inhibitor with a pharmacokinetic enhancer:

Attribute	EVOTAZ detail
Active ingredients	Atazanavir sulfate and cobicistat
Strength	Atazanavir 300 mg plus cobicistat 150 mg
Dosage form	Film-coated oral tablet
Dosing	One tablet once daily with food
Indication	HIV-1 infection in adults, in combination with other antiretroviral agents
FDA application	NDA 206353
Original U.S. approval	January 29, 2015
Sponsor	Bristol-Myers Squibb Company
Pharmacologic role	Atazanavir provides antiviral activity; cobicistat inhibits CYP3A-mediated metabolism

EVOTAZ must be administered with food because atazanavir exposure is affected by gastric and dietary conditions. The tablet is not interchangeable with separate atazanavir and cobicistat products without consideration of dose, formulation, and prescribing information requirements. The product label also identifies clinically important drug-interaction restrictions resulting from cobicistat-mediated CYP3A inhibition (U.S. Food and Drug Administration [FDA], 2015).

What excipients are used in EVOTAZ tablets?

The U.S. prescribing information identifies a conventional immediate-release tablet platform. The excipient system includes the following functional categories:

Excipient or excipient class	Primary formulation function	Commercial relevance
Lactose monohydrate	Diluent and compressibility aid	Low cost, broad availability, but unsuitable for lactose-free positioning
Microcrystalline cellulose	Diluent, dry binder, tablet-strength contributor	Supports direct compression and robust tablet manufacture
Croscarmellose sodium	Superdisintegrant	Controls tablet breakup and dissolution
Hypromellose	Binder and film-coating polymer	Supports tablet integrity and coating performance
Colloidal silicon dioxide	Glidant and moisture-management aid	Improves powder flow
Magnesium stearate	Lubricant	Controls ejection force, with potential dissolution impact if overused
Sodium lauryl sulfate	Wetting or surfactant component	May improve wetting of hydrophobic active ingredients
Titanium dioxide and coating materials	Opacifier and film-coat components	Supports appearance, light protection, and handling

Exact excipient composition should be established from the current official product label and the relevant regulatory dossier. Formulation development cannot assume that the label’s qualitative list captures quantitative ratios, granulation conditions, particle-size distributions, or supplier grades.

The combination of microcrystalline cellulose, lactose, superdisintegrant, surfactant, glidant, and lubricant is consistent with a conventional immediate-release tablet. The strategic importance lies in the balance among wetting, disintegration, compression, and dissolution. Atazanavir has low aqueous solubility, and formulation performance can be sensitive to pH, particle size, solid state, and wetting conditions. Cobicistat also contributes to the overall solubility and permeability burden.

How does EVOTAZ’s excipient system affect bioequivalence?

Bioequivalence risk is higher for EVOTAZ than for a simple, highly soluble immediate-release tablet because both active ingredients must meet exposure requirements in the same dosage form.

Four excipient variables are especially important:

1. Surfactant concentration. Sodium lauryl sulfate or a substitute can change wetting and dissolution. Excess surfactant can also alter gastrointestinal behavior and create a meaningful difference between test and reference products.

2. Disintegrant level. Croscarmellose sodium affects tablet breakup and can compensate for hydrophobic active ingredients. Over-compression, excessive lubricant, or insufficient disintegrant can delay dissolution.

3. Lubrication. Magnesium stearate is necessary for manufacturing but can create a hydrophobic tablet surface when used at high concentration or mixed for too long.

4. Particle-size and solid-state control. Excipient substitution cannot compensate for uncontrolled active pharmaceutical ingredient particle size, polymorphism, agglomeration, or milling conditions.

A generic developer should treat dissolution as a multidimensional control strategy rather than a single release test. Comparative dissolution across relevant pH conditions, fed-state modeling, and formulation robustness studies are central to reducing clinical and regulatory risk. FDA’s product-specific guidance and general bioequivalence requirements determine the final study design (FDA, 2023a; FDA, 2023b).

What excipient substitutions create the strongest commercial opportunities?

The highest-value opportunities are excipient substitutions that reduce supply risk or solve a clearly defined market problem without changing the product’s biopharmaceutical behavior.

Lactose-free EVOTAZ alternative

Replacing lactose monohydrate with mannitol, anhydrous dibasic calcium phosphate, silicified microcrystalline cellulose, or another suitable diluent could support a lactose-free product. The commercial case is strongest if the replacement improves patient access, simplifies procurement, or supports markets where lactose labeling is commercially sensitive.

The main risk is mechanical and dissolution change. Mannitol can alter compactibility and hygroscopicity. Calcium phosphate can affect density, disintegration, and pH microenvironment. Silicified cellulose can improve flow and compression but may change tablet porosity.

Global-supply excipient platform

A formulation based on multiple qualified suppliers for the diluent, disintegrant, lubricant, and coating system can reduce manufacturing interruptions. This is particularly relevant for a mature HIV product supplied through public-health tenders, where price and continuity are more important than premium branding.

The best opportunity is a formulation that maintains the same critical quality attributes across multiple excipient grades. This requires supplier-specific characterization of particle size, moisture, bulk density, viscosity, degree of substitution, and peroxide or metal content where relevant.

Direct-compression process

A direct-compression formulation could reduce capital requirements, solvent exposure, and processing time compared with wet granulation. The strategy is attractive if the active ingredients have suitable flow and compressibility after particle engineering or co-processing.

Direct compression also creates a manufacturing patent opportunity if the developer can claim a narrow combination of excipient ratios, compression force, tablet hardness, disintegration time, and dissolution profile. The claim must be supported by comparative data against the reference product.

Taste-masked or dispersible presentations

Taste masking is less commercially important for the existing adult tablet than for pediatric or adherence-oriented products. A dispersible, mini-tablet, or oral-suspension presentation could expand use in patients who cannot swallow tablets. This would be a new dosage-form strategy rather than a simple generic substitution and would require separate regulatory and clinical justification.

What formulations are most likely to receive patent protection?

Excipient patents for an EVOTAZ alternative are most defensible when they claim measurable technical results rather than a generic list of common inactive ingredients.

Potential claim areas include:

• A lactose-free composition containing atazanavir, cobicistat, a defined diluent, a superdisintegrant, and a surfactant.
• A formulation with specified dissolution performance in acidic and neutral media.
• A tablet having defined hardness, friability, disintegration time, and impurity limits.
• A moisture-stable composition with controlled water activity.
• A particle-engineered atazanavir or cobicistat composition that improves dissolution.
• A coating system that limits degradation during storage.
• A manufacturing process that produces consistent content uniformity at commercial scale.
• A formulation that remains bioequivalent under fed conditions despite excipient substitution.

Broad claims directed only to “atazanavir, cobicistat, and pharmaceutically acceptable excipients” would face substantial validity and obviousness risk because the excipients are conventional. Stronger protection would link composition ranges to unexpected dissolution, stability, manufacturability, or pharmacokinetic results.

When does EVOTAZ lose exclusivity and what is the generic-entry risk?

EVOTAZ’s commercial exclusivity depends on several separate rights:

Exclusivity category	EVOTAZ relevance
New chemical entity exclusivity	The active ingredients were previously approved, so EVOTAZ did not receive a five-year NCE period for the combination
Three-year clinical-investigation exclusivity	Potentially relevant if approval relied on qualifying new clinical investigations
Formulation patents	May cover specific dosage forms or manufacturing processes if listed or separately enforceable
Method-of-use patents	May cover treatment methods, dosing, or patient populations
Active-ingredient patents	Atazanavir and cobicistat were developed earlier and have separate patent histories
Regulatory exclusivity outside the U.S.	Depends on jurisdiction and local approval dates

The FDA Orange Book is the controlling public source for current patent listings associated with an approved small-molecule product. A definitive generic-entry analysis requires review of the current Orange Book entries, patent-use codes, regulatory exclusivity, and any litigation or settlement records (FDA, 2024).

A Paragraph IV challenge could target listed patents by asserting invalidity, non-infringement, or unenforceability. For a fixed-dose combination, the challenger may also pursue a formulation design that avoids claims directed to a particular excipient ratio or manufacturing process. The highest-risk patents for a generic applicant are usually those covering the approved combination, tablet composition, and commercially practical manufacturing method.

What FDA regulatory pathway applies to an EVOTAZ generic?

A conventional generic would generally proceed under an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant would need to demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug, satisfy quality requirements, and address any applicable patent certifications.

The principal regulatory questions are:

• Whether both active ingredients are present in the same strengths.
• Whether the dosage form and route are equivalent.
• Whether inactive-ingredient differences affect safety or performance.
• Whether food-effect behavior is adequately characterized.
• Whether dissolution is comparable across relevant conditions.
• Whether the proposed manufacturing process controls degradation and content uniformity.
• Whether the product can be manufactured consistently at commercial scale.

A major excipient change may be acceptable, but it increases the need for comparative dissolution, stability, and bioequivalence support. FDA’s inactive ingredient database can help identify previously used excipients and routes, but prior use does not establish equivalence or eliminate product-specific review (FDA, 2024b).

How strong is the excipient patent opportunity for EVOTAZ?

The opportunity is moderate for differentiated formulations and weak for routine substitution.

Strategy	Patent strength	Commercial value	Main risk
Simple lactose replacement	Low to moderate	Moderate	Obviousness and lack of unexpected results
Multi-supplier excipient platform	Low	High operational value	Trade-secret protection may be stronger than patent protection
Direct-compression process	Moderate	Moderate to high	Scale-up and content-uniformity risk
Improved dissolution composition	Moderate to strong	High	Must demonstrate clinically relevant performance
Pediatric dispersible formulation	Moderate to strong	High if regulatory demand exists	New clinical and formulation requirements
Moisture-stable tablet	Moderate	Moderate	Stability benefit must be quantified
Novel particle-engineered formulation	Stronger	High	API process complexity and freedom-to-operate risk

The most practical intellectual-property package would combine a narrow composition patent, a process patent, and confidential manufacturing know-how. Trade secrets may protect blending order, lubricant addition time, milling parameters, coating conditions, and in-process controls that are difficult to detect from the finished tablet.

Which companies are most likely to challenge or compete with EVOTAZ?

Competition is likely to come from three groups:

1. Generic pharmaceutical companies developing an atazanavir/cobicistat fixed-dose combination.
2. Manufacturers of separate atazanavir and cobicistat products, which can compete through prescribing flexibility or supply contracts.
3. Alternative HIV regimens, including integrase-inhibitor combinations that may offer simpler interaction profiles or broader prescriber familiarity.

EVOTAZ also competes indirectly with other boosted protease-inhibitor products. Cobicistat-containing regimens may face commercial pressure from unboosted or integrase-based therapies because drug interactions, renal considerations, pill burden, and guideline positioning influence treatment selection.

What commercial opportunity exists by geography?

The best geographic opportunity depends on regulatory status, reference-product availability, tender economics, and local manufacturing capability.

• United States: A generic fixed-dose tablet could benefit from simplified procurement, but Orange Book listings and Paragraph IV exposure require careful review.
• European Union: National pricing and reimbursement decisions may produce fragmented launch economics. A common formulation can reduce manufacturing complexity.
• Low- and middle-income markets: Supply continuity, low tablet cost, heat and humidity stability, and WHO or stringent-regulatory-authority acceptance may be more important than premium excipient differentiation.
• Emerging markets: Local production or technology transfer may create licensing opportunities if the formulation is robust and does not depend on a single imported excipient grade.

A moisture-stable formulation with broad supplier qualification is likely to have greater tender value than a minor aesthetic improvement. Packaging, shipping stability, and shelf-life claims should be developed alongside the excipient strategy.

What licensing deals could support an EVOTAZ excipient program?

Potential licensing structures include:

• Out-licensing a lactose-free or pediatric formulation to a regional HIV manufacturer.
• Supplying a proprietary co-processed excipient system under a technology agreement.
• Licensing a manufacturing process with minimum-volume commitments.
• Granting territorial rights for a generic fixed-dose combination.
• Partnering with a contract development and manufacturing organization that already has HIV-product registrations.
• Licensing a formulation patent while retaining ownership of process know-how.

The strongest deal economics would come from a platform that applies to multiple poorly soluble antiretroviral combinations, not EVOTAZ alone. A single-product formulation patent has narrower value unless it provides a clear regulatory, manufacturing, or market-access advantage.

Key Takeaways

• EVOTAZ contains atazanavir 300 mg and cobicistat 150 mg in a once-daily film-coated tablet.
• Its excipient platform is conventional but technically sensitive because both active ingredients have solubility and pharmacokinetic challenges.
• The strongest commercial opportunities are lactose-free formulations, direct compression, moisture-stable tablets, pediatric presentations, and multi-supplier manufacturing.
• Routine excipient substitution has limited patent strength unless supported by unexpected dissolution, stability, or bioequivalence results.
• FDA Orange Book review is essential for determining listed patents, exclusivity, Paragraph IV exposure, and potential generic-launch timing.
• Trade secrets covering process parameters and supplier-grade controls may provide more durable protection than broad excipient claims.
• Geographic value is highest where supply continuity, tender pricing, and formulation stability drive procurement decisions.

FAQs About EVOTAZ Excipient and Generic Strategy

Can lactose be removed from an EVOTAZ generic?

Yes. Lactose can potentially be replaced with mannitol, silicified microcrystalline cellulose, or another suitable diluent, but the replacement must preserve tablet strength, disintegration, dissolution, stability, and bioequivalence.

Is EVOTAZ suitable for an over-the-counter product?

No. EVOTAZ is an HIV prescription medicine with substantial drug-interaction and clinical-monitoring requirements. Its commercial pathway remains prescription-based.

Can a generic manufacturer use different excipients from EVOTAZ?

Yes. A generic may use different inactive ingredients if the product meets applicable safety, quality, pharmaceutical-equivalence, and bioequivalence requirements.

Would a pediatric EVOTAZ formulation require a new patent strategy?

Yes. A dispersible tablet, oral suspension, or mini-tablet could support separate composition, dosage-form, manufacturing, and method-of-use claims, subject to regulatory requirements.

Are EVOTAZ excipient processes better protected by patents or trade secrets?

Composition and measurable performance advantages are generally patent candidates. Blending order, processing conditions, supplier qualification, and scale-up controls may be better protected as trade secrets when they cannot be identified from the finished product.

References

1. U.S. Food and Drug Administration. (2015). EVOTAZ (atazanavir sulfate and cobicistat) tablets: U.S. prescribing information. Bristol-Myers Squibb Company.

2. U.S. Food and Drug Administration. (2023a). Guidance for industry: Bioavailability and bioequivalence studies submitted in NDAs or INDs: General considerations. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2023b). Product-specific guidance for generic drug development. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2024b). Inactive ingredient database. Center for Drug Evaluation and Research.